Welcome to our dedicated page for Catalyst Pharmaceuticals SEC filings (Ticker: CPRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) SEC filings page on Stock Titan provides structured access to the company’s official disclosures filed with the U.S. Securities and Exchange Commission. As a commercial-stage biopharmaceutical company focused on rare and difficult-to-treat diseases, Catalyst uses its filings to report on financial performance, material events, capital allocation decisions, and developments affecting its product portfolio, including FIRDAPSE, AGAMREE, and FYCOMPA.
Investors can review current reports on Form 8-K, where Catalyst discloses events such as quarterly financial results, authorization of share repurchase programs, patent litigation settlements related to FIRDAPSE, changes to clinical practice guidelines referencing Lambert-Eaton myasthenic syndrome and amifampridine, and updates to its Board of Directors. These filings often incorporate press releases as exhibits, providing additional context on how specific events may influence the company’s operations and CPRX stock.
In addition to event-driven 8-Ks, users can access periodic reports like Forms 10-Q and 10-K, which contain detailed discussions of product revenue, research and development spending, selling and administrative costs, and other aspects of Catalyst’s business. For a biopharmaceutical issuer, these reports are key resources for understanding revenue contributions from individual products, the status of rare disease programs, and the company’s approach to intellectual property and litigation.
Stock Titan enhances these documents with AI-powered summaries that highlight the main points of lengthy filings, helping users quickly identify items such as revenue trends, material agreements, or litigation outcomes. The platform also surfaces insider transaction reports on Form 4 when available, giving additional visibility into trading activity by officers and directors. With real-time updates from EDGAR and simplified explanations of complex regulatory documents, this CPRX filings page supports efficient, in-depth analysis of Catalyst Pharmaceuticals’ regulatory record.
Catalyst Pharmaceuticals (CPRX) reported insider equity awards for its Chief Compliance/Legal Officer on a Form 4. On November 20, 2025, the officer received options to purchase 98,652 shares of common stock at an exercise price of $22.77 per share, expiring on November 20, 2032. These options vest in three equal annual installments on November 20 of 2026, 2027, and 2028.
The officer was also granted 29,776 restricted stock units (RSUs), which convert into common shares upon vesting, with the same three-year vesting schedule. On November 21, 2025, 5,161 shares underlying RSUs were delivered, while 2,030 shares were withheld to cover taxes. After these transactions, the officer directly held 234,170 shares of common stock and 969,876 derivative securities, mainly options and RSUs.
Catalyst Pharmaceuticals, Inc. (CPRX) reported insider equity activity for its Chief Commercial Officer on a Form 4. On 11/21/2025, the officer exercised 5,603 shares of common stock and had 1,641 shares withheld to cover taxes, leaving 3,962 common shares beneficially owned directly. The filing also shows a grant on 11/20/2025 of options to purchase 106,873 shares of common stock at an exercise price of $22.77, vesting in three equal annual installments on November 20, 2026, 2027 and 2028. In addition, the officer received 32,257 restricted stock units tied to common stock, and RSUs covering 5,603 shares were settled into stock on 11/21/2025. Following these transactions, the officer holds 1,064,535 derivative securities, including options and RSUs, all reported as directly owned.
Catalyst Pharmaceuticals, Inc. (CPRX) director Daniel J. Curran reported new equity awards dated 11/20/2025. He received options to purchase 18,115 shares of common stock at an exercise price of $22.77 per share, which vest in three equal annual installments on November 20, 2026, 2027 and 2028. Following this grant, he beneficially owns 58,115 stock options. He was also awarded 5,468 restricted stock units (RSUs), each representing a right to receive one share of common stock upon vesting, increasing his RSU holdings to 63,583 units. All holdings are reported as directly owned.
Catalyst Pharmaceuticals (CPRX) reported an equity award for its Chief Medical Officer on a Form 4. On November 20, 2025, the officer received options to purchase 98,652 shares of common stock at an exercise price of $22.77 per share, expiring on November 20, 2032. The grant also included 29,776 restricted stock units (RSUs), each representing one share of common stock upon vesting.
The derivative securities vest in three equal parts: one‑third on November 20, 2026, one‑third on November 20, 2027, and one‑third on November 20, 2028. After these awards, the officer beneficially owns 238,360 options and 268,136 RSUs in total, aligning compensation with the company’s long-term stock performance.
Catalyst Pharmaceuticals (CPRX) reported that it issued a press release on November 5, 2025 announcing results for the three and nine months ended September 30, 2025, along with a business update. The press release is furnished as Exhibit 99.1. This routine update signals that quarterly and year-to-date performance details are available via the attached exhibit, which also serves as the company’s formal communication of its latest operating highlights.
Catalyst Pharmaceuticals (CPRX) reported stronger Q3 2025 results. Total revenue reached $148.4 million, up from $128.7 million a year ago, driven by FIRDAPSE ($92.2 million), AGAMREE ($32.4 million), and FYCOMPA ($23.8 million). Operating income was $66.3 million and net income was $52.8 million, with diluted EPS of $0.42 versus $0.35 last year.
For the nine months, revenue rose to $436.4 million from $349.9 million, and net income increased to $161.6 million from $108.0 million. Cash and cash equivalents were $689.9 million, supported by $163.8 million in operating cash flow year-to-date. The balance sheet shows total assets of $1.05 billion, liabilities of $131.4 million, and stockholders’ equity of $920.2 million. Shares outstanding were 122,912,387 as of November 3, 2025.
Catalyst Pharmaceuticals, Inc. disclosed that its Board of Directors has approved a share repurchase program authorizing the company to buy back up to $200 million of its common stock. The program runs from October 1, 2025 through December 31, 2026.
The company may repurchase shares through methods such as open market purchases or privately negotiated transactions. The timing and amount of any repurchases will depend on factors including stock price, business and market conditions, regulatory requirements, and alternative investment or acquisition opportunities. Catalyst plans to use existing cash on hand to fund the program, is not obligated to repurchase any specific amount, and may suspend or terminate the program at any time.
Brian Elsbernd, Chief Compliance/Legal Officer and Director of Catalyst Pharmaceuticals, reported option exercises and an open-market sale on 09/08/2025. He exercised 112,475 options at an exercise price of $2.24 per share, resulting in the acquisition of 112,475 common shares. To fund the exercise price and tax withholding, 30,000 shares were sold on the open market at a weighted average price of $20.30 (sales ranged from $20.225 to $20.315). Following these transactions, Mr. Elsbernd beneficially owned 271,039 shares directly and reported 846,609 derivative securities (options) beneficially owned. The options reported vested in three annual tranches beginning December 19, 2019.
Catalyst Pharmaceuticals (CPRX) filing a Form 144 notifies of a proposed sale of 30,000 common shares to be executed through Fidelity Brokerage Services on 09/08/2025 with an aggregate market value of $609,035.49 based on the filing. The shares were acquired through options granted 12/19/2018 and the reported payment method for the sale is cash. The filing also reports recent open-market disposals by the same person: 20,000 shares sold on 09/03/2025 for $401,514.00 and 30,000 shares sold on 09/04/2025 for $585,642.00. The filer attests no undisclosed material adverse information.
Catalyst Pharmaceuticals insider Brian Elsbernd, listed as the company's Chief Compliance/Legal Officer, reported option exercises and open-market sales on 09/03/2025 and 09/04/2025. He exercised 20,000 options on 09/03/2025 at a $2.24 exercise price and sold 20,000 common shares that day for a weighted average of $20.08 per share. On 09/04/2025 he exercised another 30,000 options at $2.24 and sold 30,000 shares for a weighted average of $19.52 per share. Following these transactions his beneficial ownership in common stock is reported as 188,564 shares and the filing shows remaining option positions underlying 989,084 and 959,084 shares after each exercise event as reported in Table II. The filing states the sales were on the open market for personal reasons and not due to any disagreement with the company.